• SMYD2 Inhibition Reverses Drug Resistance in Renal Cell Carc

  2026-04-19

  This study demonstrates that targeting the histone methyltransferase SMYD2 suppresses tumor progression and overcomes multidrug resistance in clear cell renal cell carcinoma (ccRCC) by downregulating miR-125b and P-glycoprotein. The findings offer a mechanistic rationale for integrating epigenetic modulation with established chemotherapeutic agents in research on treatment-resistant cancers.

• TAI-1 Hec1 Inhibitor: Precision Workflows for Cancer Researc

  2026-04-18

  TAI-1 sets a new benchmark as a potent, first-in-class Hec1 inhibitor, enabling targeted mitotic disruption and robust apoptotic cell death induction. This guide translates recent mechanistic discoveries and reference study insights into actionable workflows, troubleshooting strategies, and advanced applications across diverse cancer research models.

• 3-Bromopyruvate Induces Ferroptosis to Overcome Cetuximab Re

  2026-04-17

  This study demonstrates that co-treatment with 3-bromopyruvate and cetuximab can overcome both intrinsic and acquired resistance to cetuximab in colorectal cancer cells by triggering autophagy-dependent ferroptosis and apoptosis. Mechanistic insights highlight the restoration of FOXO3a signaling as central to these effects, suggesting a promising therapeutic avenue for resistant colorectal cancer.

• Mubritinib–HSA Binding: Mechanistic Insights for Pharmacolog

  2026-04-16

  This study advances the understanding of how mubritinib, a mitochondrial complex I inhibitor with anti-cancer properties, interacts with human serum albumin (HSA). By employing multiple spectroscopic and molecular docking methods, the research elucidates key aspects of mubritinib’s binding affinity, site specificity, and resulting protein functional changes—findings relevant for drug development and optimizing pharmacokinetics.

• PSA-CD56/Siglec-7 Axis Drives Immune Evasion in ccRCC

  2026-04-15

  This study uncovers polysialylated CD56 (PSA-CD56) as a novel glyco-immune checkpoint in clear cell renal cell carcinoma (ccRCC), mediating immune evasion by engaging Siglec-7 on CD8+ T cells. The findings have significant implications for overcoming immunotherapy resistance and guiding apoptosis and necrosis detection strategies in translational research.

• GANT61 Triggers Apoptosis in ALK+ ALCL via Hh-PIK3IP1-Akt Ax

  2026-04-14

  This study elucidates how GANT61, a direct Gli1/2 inhibitor, suppresses proliferation and induces apoptosis in ALK-positive anaplastic large cell lymphoma (ALK+ ALCL) by modulating the Hh-PIK3IP1-Akt signaling network. The findings provide mechanistic clarity on targeting the Hedgehog pathway and offer practical insight for designing apoptosis detection assays in hematologic malignancy research.

• Concanamycin A: V-type H+-ATPase Inhibitor in Cancer Workflo

  2026-04-13

  Concanamycin A empowers cancer biologists to probe V-ATPase signaling, apoptosis, and invasion mechanisms with nanomolar precision. This article details stepwise protocols and troubleshooting strategies, translating advanced research and the latest reference study into actionable insights for maximizing data quality.

• Methylprednisolone Sodium Succinate: Precision Dosing in Adv

  2026-04-13

  Explore the nuanced pharmacology and precision assay design potential of Methylprednisolone Sodium Succinate, a leading synthetic corticosteroid. This article delivers new insights on dosing, receptor dynamics, and translational research choices beyond typical mechanistic reviews.

• XPO1 Inhibition Reduces CRC Tumorigenesis via Wnt/β-Catenin

  2026-04-12

  This study demonstrates that Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, suppresses colorectal cancer (CRC) development by modulating the Wnt/β-catenin pathway. The findings underscore the mechanistic basis for XPO1 targeting as a chemopreventive strategy, offering translational insights for cancer research workflows.

• SM-164: Bivalent Smac Mimetic for Precision Apoptosis Induct

  2026-04-12

  SM-164 is redefining apoptosis induction in cancer research thanks to its high-affinity, bivalent inhibition of IAPs and rapid, TNFα-dependent tumor cell killing. This guide details evidence-driven workflows, troubleshooting, and advanced use-cases to maximize assay sensitivity and reproducibility. Harness the robust, reproducible performance of SM-164 from APExBIO to unlock new insights into cell death mechanisms.

• Cyclophosphamide as an Alkylating Chemotherapeutic Agent: Wo

  2026-04-11

  Cyclophosphamide is a cornerstone alkylating chemotherapeutic agent, pivotal for both cancer research and immunomodulation. This guide translates bench-level protocols and recent reference breakthroughs into practical workflows, with troubleshooting tips and comparative insights for reproducible apoptosis induction and bone marrow transplantation conditioning.

• Hydroxytyrosol in Oxidative Stress and Cardiovascular Resear

  2026-04-11

  Hydroxytyrosol, a high-purity olive oil phenolic, empowers oxidative stress and anti-inflammatory research with reproducible, quantifiable effects. This guide delivers stepwise protocols, troubleshooting insights, and application-driven recommendations, translating new mechanistic findings into robust experimental outcomes.

• N-Acetylneuraminic Acid: Technical Guide for Lab Researchers

  2026-04-10

  N-Acetylneuraminic acid is a well-characterized human endogenous metabolite critical for studies of cell surface glycoproteins and their roles in cell recognition, adhesion, and tumor biology. This product is intended for advanced research workflows requiring high-purity, water-soluble metabolite preparations. It is not suitable for diagnostic or medical applications and should only be used under controlled laboratory protocols.

• Advancing Translational Research: Mechanistic and Strateg...

  2026-04-10

  This thought-leadership article explores how the APExBIO Cell Counting Kit-8 (CCK-8), with its advanced WST-8 chemistry, is transforming cell viability, proliferation, and cytotoxicity assays across cancer, metabolic, and regenerative research. Integrating recent mechanistic findings—including the Prmt1-Ddx17-Sh2b1 axis in osteoblast differentiation—the article provides a strategic roadmap for translational researchers, distinguishing itself by connecting biological rationale, competitive advantage, and visionary translational pathways far beyond standard product descriptions.

• Cyclosporin A: Precision Applications in Immunosuppressio...

  2026-04-09

  Cyclosporin A is a benchmark cyclophilin inhibitor and immunosuppressive agent, empowering researchers to tackle autoimmune diseases, apoptosis, and viral entry with unmatched workflow reliability. Leveraging APExBIO's Cyclosporin A, you gain superior reproducibility and mechanistic clarity for cell and animal models. This in-depth guide navigates experimental setup, advanced applications, and troubleshooting for translational and bench research.

13786 records 5/920 page Previous Next 12345 下5页 Last page